Aprea Therapeutics Analyst Ratings
Aprea Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/01/2023 | 284.62% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 09/13/2023 | 284.62% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 08/10/2023 | 284.62% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 05/16/2023 | 284.62% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 03/10/2023 | 207.69% | Maxim Group | → $16 | Initiates Coverage On | → Buy |
| 10/10/2022 | -42.31% | HC Wainwright & Co. | → $3 | Assumes | → Buy |
| 07/08/2022 | -42.31% | Wedbush | → $3 | Initiates Coverage On | → Outperform |
| 03/16/2022 | -61.54% | HC Wainwright & Co. | $4 → $2 | Maintains | Neutral |
| 03/16/2022 | -23.08% | RBC Capital | $5 → $4 | Maintains | Sector Perform |
| 08/20/2021 | — | JP Morgan | Downgrades | Neutral → Underweight | |
| 08/16/2021 | — | Berenberg | Downgrades | Buy → Hold | |
| 08/16/2021 | -23.08% | HC Wainwright & Co. | $6 → $4 | Maintains | Neutral |
| 08/13/2021 | -3.85% | RBC Capital | $6 → $5 | Maintains | Sector Perform |
| 08/13/2021 | -42.31% | Morgan Stanley | $5 → $3 | Downgrades | Equal-Weight → Underweight |
| 03/17/2021 | 53.85% | RBC Capital | $10 → $8 | Maintains | Sector Perform |
| 12/29/2020 | 92.31% | RBC Capital | $40 → $10 | Downgrades | Outperform → Sector Perform |
| 12/16/2020 | 553.85% | Morgan Stanley | $39 → $34 | Maintains | Equal-Weight |
| 12/16/2020 | 611.54% | Berenberg | → $37 | Initiates Coverage On | → Buy |
| 06/22/2020 | 476.92% | HC Wainwright & Co. | → $30 | Initiates Coverage On | → Neutral |
| 04/21/2020 | 765.38% | Baird | → $45 | Initiates Coverage On | → Outperform |
| 04/15/2020 | 650% | Morgan Stanley | $36 → $39 | Maintains | Equal-Weight |
| 03/27/2020 | 592.31% | Morgan Stanley | $23 → $36 | Maintains | Equal-Weight |
| 10/28/2019 | 342.31% | JP Morgan | → $23 | Initiates Coverage On | → Neutral |
| 10/28/2019 | 342.31% | Morgan Stanley | → $23 | Initiates Coverage On | → Equal-Weight |
| 10/28/2019 | 534.62% | RBC Capital | → $33 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年11月1日 | 284.62% | HC Wainwright公司 | →$20 | 重申 | 購買→購買 |
| 09/13/2023 | 284.62% | HC Wainwright公司 | →$20 | 重申 | 購買→購買 |
| 2023年08月10日 | 284.62% | HC Wainwright公司 | →$20 | 重申 | 購買→購買 |
| 2023年05月16日 | 284.62% | HC Wainwright公司 | →$20 | 重申 | 購買→購買 |
| 03/10/2023 | 207.69% | Maxim集團 | →$16 | 開始承保 | →購買 |
| 2022年10月10日 | -42.31% | HC Wainwright公司 | →$3 | 假設 | →購買 |
| 07/08/2022 | -42.31% | 韋德布什 | →$3 | 開始承保 | →跑贏大盤 |
| 03/16/2022 | -61.54% | HC Wainwright公司 | $4→$2 | 維護 | 中性 |
| 03/16/2022 | -23.08% | 加拿大皇家銀行資本 | $5→$4 | 維護 | 行業表現 |
| 08/20/2021 | - | 摩根大通 | 評級下調 | 中性→減持 | |
| 08/16/2021 | - | 貝倫伯格 | 評級下調 | 購買→Hold | |
| 08/16/2021 | -23.08% | HC Wainwright公司 | $6→$4 | 維護 | 中性 |
| 2021/08/13 | -3.85% | 加拿大皇家銀行資本 | $6→$5 | 維護 | 行業表現 |
| 2021/08/13 | -42.31% | 摩根士丹利 | $5→$3 | 評級下調 | 等重→減碼 |
| 03/17/2021 | 53.85% | 加拿大皇家銀行資本 | $10→$8 | 維護 | 行業表現 |
| 12/29/2020 | 92.31% | 加拿大皇家銀行資本 | $40→$10 | 評級下調 | 跑贏→板塊表現 |
| 12/16/2020 | 553.85% | 摩根士丹利 | $39→$34 | 維護 | 等重 |
| 12/16/2020 | 611.54% | 貝倫伯格 | →$37 | 開始承保 | →購買 |
| 06/22/2020 | 476.92% | HC Wainwright公司 | →$30 | 開始承保 | →中性 |
| 04/21/2020 | 765.38% | 貝爾德 | →$45 | 開始承保 | →跑贏大盤 |
| 04/15/2020 | 650% | 摩根士丹利 | $36→$39 | 維護 | 等重 |
| 03/27/2020 | 592.31% | 摩根士丹利 | $23→$36 | 維護 | 等重 |
| 2019年10月28日 | 342.31% | 摩根大通 | →$23 | 開始承保 | →中性 |
| 2019年10月28日 | 342.31% | 摩根士丹利 | →$23 | 開始承保 | →等重 |
| 2019年10月28日 | 534.62% | 加拿大皇家銀行資本 | →$33 | 開始承保 | →跑贏大盤 |
What is the target price for Aprea Therapeutics (APRE)?
Aprea治療公司(APRE)的目標價格是多少？
The latest price target for Aprea Therapeutics (NASDAQ: APRE) was reported by HC Wainwright & Co. on November 1, 2023. The analyst firm set a price target for $20.00 expecting APRE to rise to within 12 months (a possible 284.62% upside). 5 analyst firms have reported ratings in the last year.
阿普雷亞治療公司(納斯達克代碼：APRE)的最新目標價是由HC Wainwright&Co.於2023年11月1日報道的。這家分析公司將目標價定為20美元，預計平均收益率將在12個月內升至(可能上漲284.62)。去年有5家分析公司公佈了評級。
What is the most recent analyst rating for Aprea Therapeutics (APRE)?
Aprea治療公司(APRE)的最新分析師評級是多少？
The latest analyst rating for Aprea Therapeutics (NASDAQ: APRE) was provided by HC Wainwright & Co., and Aprea Therapeutics reiterated their buy rating.
Aprea治療公司(納斯達克代碼：APRE)的最新分析師評級由HC Wainwright&Co.提供，Aprea治療公司重申其買入評級。
When is the next analyst rating going to be posted or updated for Aprea Therapeutics (APRE)?
Aprea治療公司(APRE)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aprea Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aprea Therapeutics was filed on November 1, 2023 so you should expect the next rating to be made available sometime around November 1, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Aprea治療公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Aprea治療公司的上一次評級是在2023年11月1日提交的，所以你應該預計下一次評級將在2024年11月1日左右的某個時候提供。
Is the Analyst Rating Aprea Therapeutics (APRE) correct?
分析師對Aprea Treeutics(APRE)的評級正確嗎？
While ratings are subjective and will change, the latest Aprea Therapeutics (APRE) rating was a reiterated with a price target of $0.00 to $20.00. The current price Aprea Therapeutics (APRE) is trading at is $5.20, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Aprea治療(APRE)評級被重申，目標價在0.00美元至20.00美元之間。目前Aprea治療公司(APRE)的交易價格為5.20美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。